Sutimlimab Protects Blood Cells Over Time to Improve Life Quality, Trials Report

Sutimlimab Protects Blood Cells Over Time to Improve Life Quality, Trials Report

294375

Sutimlimab Protects Blood Cells Over Time to Improve Life Quality, Trials Report

Sutimlimab continues to lessen the need for blood transfusions, prevent red blood cell destruction, ease fatigue, and limit inflammation in patients with primary cold agglutinin disease (CAD), according to data from two Phase 3 trials. These findings will be presented by Sanofi, the investigational therapy’s developer, at the 26th Annual European Hematology Association (EHA) Virtual Congress set for June 9–17. “The data being presented at EHA 2021 demonstrate Sanofi’s commitment to providing first-in-class and potentially transformative treatments for people…

You must be logged in to read/download the full post.